Treatment Intensification for Advanced Prostate Cancer Podcast (2023)
Based on the documented need for additional education in prostate cancer, bladder cancer, and kidney cancer, the AUA has developed AUA Expert Exchange Podcast: Discussions in GU Cancer. The 2023 AUA Expert Exchange Podcast: Discussions in GU Cancer is designed to address very specific learning opportunities and reach the urologic practitioners in an easy, flexible way with smaller, targeted updates. To address the educational needs of the urologic care team, this episode will focus on:
Treatment Intensification for Advanced Prostate Cancer (2023)
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
Astellas and Pfizer, Inc.
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.
Target Audience
- Urologists
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Identify the latest developments in hormone therapy for advanced prostate cancer, including the use of novel treatments and combinations.
- Discuss the concept of doublet and triplet therapy in advanced prostate cancer and its rationale in enhancing treatment efficacy.
- Consider the challenges and future directions in implementing doublet and triplet therapy in clinical practice, including cost, accessibility, and patient selection.
FACULTY DISCLOSURES
Name | Company Name | Relationship Type | End Date |
Morgans, Alicia | Bayer | Consultant or Advisor | Current |
Morgans, Alicia | Astra Zeneca | Consultant or Advisor | Current |
Morgans, Alicia | Astellas | Consultant or Advisor | Current |
Morgans, Alicia | Sanofi | Consultant or Advisor | Current |
Morgans, Alicia | Genetech | Consultant or Advisor | 12/30/2021 |
Morgans, Alicia | Genetech | Consultant or Advisor | 12/30/2021 |
Morgans, Alicia | Janssen | Consultant or Advisor | Current |
Morgans, Alicia | Clovis | Consultant or Advisor | 12/30/2021 |
Morgans, Alicia | Dendreon | Consultant or Advisor | Current |
Morgans, Alicia | Merck | Consultant or Advisor | Current |
Morgans, Alicia | BMS | Consultant or Advisor | Current |
Morgans, Alicia | Pfizer | Consultant or Advisor | Current |
Morgans, Alicia | Myovant | Consultant or Advisor | Current |
Morgans, Alicia | Advanced Accelerator Applications | Consultant or Advisor | Current |
Morgans, Alicia | Advanced Accelerator Applications | Consultant or Advisor | Current |
Morgans, Alicia | Progenics | Consultant or Advisor | 12/30/2021 |
Morgans, Alicia | Lantheus | Consultant or Advisor | Current |
Morgans, Alicia | Myriad | Consultant or Advisor | Current |
Morgans, Alicia | Telix | Consultant or Advisor | Current |
Morgans, Alicia | Novartis | Consultant or Advisor | Current |
Moul, Judd W. | Sanofi-Aventis | Meeting Participant or Lecturer | Current |
Moul, Judd W. | Theralogix | Consultant or Advisor | Current |
Moul, Judd W. | Janssen- J and J | Meeting Participant or Lecturer | Current |
Moul, Judd W. | Pfizer | Scientific Study or Trial | Current |
Moul, Judd W. | Astellas | Meeting Participant or Lecturer | Current |
Moul, Judd W. | Tolmar | Consultant or Advisor | Current |
Moul, Judd W. | Exosome Dx | Meeting Participant or Lecturer | Current |
Moul, Judd W. | Blue Earth Diagnostics | Meeting Participant or Lecturer | Current |
Moul, Judd W. | Bayer | Consultant or Advisor | Current |
Moul, Judd W. | Dendreon | Meeting Participant or Lecturer | Current |
Moul, Judd W. | Myovant | Scientific Study or Trial | Current |
Raman, Jay D. | Nothing relevant to disclose |
EDUCATION COUNCIL DISCLOSURES
Education Council Disclosures 2023.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Work Group Disclosures_2023.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
AUA ACCREDITATION INFORMATION
Method of Participation: Learners will participate in this online educational activity by listening to the podcast, answering multiple choice questions, examining patient tools and resources and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 0.50 hours
Release Date: November, 2023
Expiration Date: November, 2024
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Non-Physician Participation